Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)

References

• Liu X, Cui Y, Zhang Y, Liu Z, Zhang Q, Wu W, Zheng Z, Li S, Zhang Z, Li Y. A comprehensive study of immunology repertoires in both preoperative stage and postoperative stage in patients with colorectal cancer. Mol Genet Genomic Med. 2019;7(3):e504. doi:10.1002/mgg3.504.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al. Neoadjuvant PD-1 blockade in resectable lung Cancer. N Engl J Med. 2018;378(21):1976–10. doi:10.1056/NEJMoa1716078.
   PubMed Web of Science ®Google Scholar
• Lee JB, Kim HR, Ha S-J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in Cancer immunotherapy. Immune Netw. 2022;22(1):e2. doi:10.4110/in.2022.22.e2.
   PubMed Web of Science ®Google Scholar
• Falzone L, Salomone S, Libra M. Evolution of Cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300. doi:10.3389/fphar.2018.01300.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Luan J, Song L, Cong R, Ji C, Zhou X, Xia J, Song N. Age-related differences in molecular profiles for immune checkpoint blockade therapy. Front Immunol. 2021;12:657575. doi:10.3389/fimmu.2021.657575.
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, et al. Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis. Eur Urol. 2022;81(4):414–25. doi:10.1016/j.eururo.2022.01.028.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–34. doi:10.1038/s41590-019-0512-0.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in Cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–26. doi:10.1016/j.cell.2018.09.035.
   PubMed Web of Science ®Google Scholar
• Feng R, Chen Y, Liu Y, Zhou Q, Zhang W. The role of B7-H3 in tumors and its potential in clinical application. Int Immunopharmacol. 2021;101:108153. doi:10.1016/j.intimp.2021.108153.
   PubMed Web of Science ®Google Scholar
• Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA. 2008;105(30):10277–8. doi:10.1073/pnas.0805458105.
   PubMed Web of Science ®Google Scholar
• Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol. 2001;2(3):269–74. doi:10.1038/85339.
   PubMed Web of Science ®Google Scholar
• Li G, Quan Y, Che F, Wang L. B7-H3 in tumors: friend or foe for tumor immunity? Cancer Chemother Pharmacol. 2018;81(2):245–53. doi:10.1007/s00280-017-3508-1.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77. doi:10.1038/nri2326.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang H-L, Li Z-L, Du T, Chen Y-H, Wang Y, Ni H-H, Zhang K-M, Mai J, Hu B-X, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672. doi:10.1038/s41467-021-22618-x.
   PubMed Web of Science ®Google Scholar
• Zhou Y-H, Chen Y-J, Ma Z-Y, Xu L, Wang Q, Zhang G-B, Xie F, Ge Y, Wang X-F, Zhang X-G. 4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells. Tissue Antigens. 2007;70(2):96–104. doi:10.1111/j.1399-0039.2007.00853.x.
   PubMedGoogle Scholar
• Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 2008;123(4):538–46. doi:10.1111/j.1365-2567.2007.02723.x.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu P, Wang Y, Nie W, Li Z, Xu W, Li F, Zhou Z, Zhao M, Liu H, et al. Characterization of a Soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the Sera of patients with hepatocellular carcinoma. PLoS One. 2013;8(10):e76965. doi:10.1371/journal.pone.0076965.
   PubMed Web of Science ®Google Scholar
• Prasad DVR, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500–6. doi:10.4049/jimmunol.173.4.2500.
   PubMed Web of Science ®Google Scholar
• Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Li P, Lyu N, Sun T, Xie S, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–36. doi:10.1038/s41423-019-0305-2.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang G-B, Gan W-J, Xiong F, Li Z, Zhao H, Zhu D-M, Zhang B, Zhang X-G, Li D-C. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. 2013;5(3):805–12. doi:10.3892/ol.2013.1118.
   PubMed Web of Science ®Google Scholar
• Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016;7(6):6891–901. doi:10.18632/oncotarget.6902.
   PubMedGoogle Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human Cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–31. doi:10.1158/1078-0432.CCR-15-2428.
   PubMed Web of Science ®Google Scholar
• Cheng N, Bei Y, Song Y, Zhang W, Xu L, Zhang W, Yang N, Bai X, Shu Y, Shen P. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochem Pharmacol. 2021;183:114298. doi:10.1016/j.bcp.2020.114298.
   PubMed Web of Science ®Google Scholar
• Zhou W-T, Jin W-L. B7-H3/CD276: An emerging Cancer immunotherapy. Front Immunol [Internet]. 2021;12. [accessed 2023 Jan 12]. https://www.frontiersin.org/articles/10.3389/fimmu.2021.701006/full.
   Web of Science ®Google Scholar
• Li Z-Y, Wang J-T, Chen G, Shan Z-G, Wang T-T, Shen Y, Chen J, Yan Z-B, Peng L-S, Mao F-Y, et al. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer. Clin Immunol. 2021;227:108753. doi:10.1016/j.clim.2021.108753.
   PubMed Web of Science ®Google Scholar
• Zhang W, Acuna-Villaorduna A, Kuan K, Gupta S, Hu S, Ohaegbulam K, Albanese J, Kaumaya M, Levy R, Hwang RR, et al. B7-H3 and PD-L1 expression are prognostic biomarkers in a multi-racial cohort of patients with colorectal Cancer. Clin Colorectal Cancer. 2021;20(2):161–9. doi:10.1016/j.clcc.2021.02.002.
   PubMed Web of Science ®Google Scholar
• Zhao B, Li H, Xia Y, Wang Y, Wang Y, Shi Y, Xing H, Qu T, Wang Y, Ma W. Immune checkpoint of B7-H3 in Cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2020;15(1):153. doi:10.1186/s13045-022-01364-7.
   Web of Science ®Google Scholar
• Chen C, Song M, Glanzel W. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994. doi:10.1371/journal.pone.0223994.
   PubMed Web of Science ®Google Scholar
• Roldan-Valadez E, Salazar-Ruiz SY, Ibarra-Contreras R, Rios C. Current concepts on bibliometrics: a brief review about impact factor, eigenfactor score, CiteScore, SCImago journal Rank, source-normalised impact per paper, H-index, and alternative metrics. Ir J Med Sci. 2019;188:939–51. doi:10.1007/s11845-018-1936-5.
   PubMed Web of Science ®Google Scholar
• Sun T-W, Gao Q, Qiu S-J, Zhou J, Wang X-Y, Yi Y, Shi J-Y, Xu Y-F, Shi Y-H, Song K, et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother. 2012;61(11):2171–82. doi:10.1007/s00262-012-1278-5.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, Cao N, Liu L, Zhang Y, Marie PJ. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One. 2013;8(8):e70689. doi:10.1371/journal.pone.0070689.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Euro J Surg Oncol (EJSO). 2014;40(1):121–7. doi:10.1016/j.ejso.2013.08.023.
   PubMed Web of Science ®Google Scholar
• Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6(5):3452–61. doi:10.18632/oncotarget.3097.
   PubMedGoogle Scholar
• Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, et al. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer. 2017;103:44–51. doi:10.1016/j.lungcan.2016.11.013.
   PubMed Web of Science ®Google Scholar
• Lee Y, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim B-S, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–45. doi:10.1038/cr.2017.90.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, et al. B7-H3 negatively modulates CTL-Mediated Cancer immunity. Clin Cancer Res. 2018;24(11):2653–64. doi:10.1158/1078-0432.CCR-17-2852.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–74. doi:10.1158/1078-0432.CCR-18-0432.
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221–37.e8. doi:10.1016/j.ccell.2019.01.002.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang NP, Zandberg D, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022;10(4):e004424. doi:10.1136/jitc-2021-004424.
   PubMed Web of Science ®Google Scholar
• Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99. doi:10.1038/s41573-019-0051-2.
   PubMed Web of Science ®Google Scholar
• Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 2020;26(5):712–9. doi:10.1038/s41591-020-0821-8.
   PubMed Web of Science ®Google Scholar
• Haydar D, Houke H, Chiang J, Yi Z, Odé Z, Caldwell K, Zhu X, Mercer KS, Stripay JL, Shaw TI, et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 2021;23(6):999–1011. doi:10.1093/neuonc/noaa278.
   PubMed Web of Science ®Google Scholar
• Pinto NR, Albert CM, Taylor M, Wilson A, Rawlings-Rhea S, Huang W, Seidel K, Narayanaswany P, Wu V, Brown C. STRIVE-02: a first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors. J Clin Oncol. 2022;40(16_suppl):10011–10011. doi:10.1200/JCO.2022.40.16_suppl.10011.
   Web of Science ®Google Scholar
• Wang C, Li Y, Jia L, Kim JK, Li J, Deng P, Zhang W, Krebsbach PH, Wang C-Y. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28(9):1597–1613.e7. doi:10.1016/j.stem.2021.04.011.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang F, Yang D, Gao A, Lin W, Ma X, et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):13987–95.
   PubMed Web of Science ®Google Scholar
• Crine SL, Acharya KR. Molecular basis of C‐mannosylation – a structural perspective. FEBS J. 2022;289(24):7670–87. doi:10.1111/febs.16265.
   PubMed Web of Science ®Google Scholar